Recent Quotes (30 days)

You have no recent quotes
chg | %

Omeros Corporation  

(Public, NASDAQ:OMER)   Watch this stock  
Find more results for OMER
19.81
-0.14 (-0.70%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.31 - 20.41
52 week 8.71 - 27.09
Open 19.96
Vol / Avg. 931,011.00/1.19M
Mkt cap 950.95M
P/E     -
Div/yield     -
EPS -1.29
Shares 48.00M
Beta 3.52
Inst. own 51%
Nov 9, 2017
Q3 2017 Omeros Corp Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -34.55% -160.38%
Operating margin -23.59% -143.86%
EBITD margin - -129.70%
Return on average assets -32.29% -114.81%
Return on average equity - -
Employees 154 -
CDP Score - -

Address

201 Elliott Ave W
SEATTLE, WA 98119-4240
United States - Map
+1-206-6765000 (Phone)
+1-206-6765005 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

Officers and directors

Gregory A. Demopulos M.D. Chairman of the Board, President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Michael A. Jacobsen Chief Accounting Officer, Vice President - Finance, Treasurer
Age: 58
Bio & Compensation  - Reuters
Marcia S. Kelbon J.D. Vice President - Patent, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Thomas J. Cable Lead Independent Director
Age: 77
Bio & Compensation  - Reuters
Peter A. Demopulos M.D. Director
Age: 61
Bio & Compensation  - Reuters
Ray Aspiri Independent Director
Age: 78
Bio & Compensation  - Reuters
Arnold C. Hanish Independent Director
Age: 69
Bio & Compensation  - Reuters
Leroy E. Hood M.D., Ph.D. Independent Director
Age: 78
Bio & Compensation  - Reuters